FDA has approved Yescarta (axicabtagene ciloleucel), a genetically modified cell therapy, to treat adult patients with certain types of large B cell lymphoma who have not responded to or have relapsed after at least two other kinds of treatment.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following
Argos Therapeutics Inc. reported on an update on the interim analysis of data from the ongoing phase III ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma was presented by Robert Figlin, professor and chairman, division of hematology and oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid.
Pfizer Inc. and Astellas Pharma Inc. announced the phase III PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.
A new Cleveland Clinic study underscores the importance of early detection and treatment of melanoma, the deadliest form of skin cancer.
An analysis led by researchers at Fox Chase Cancer Center in collaboration with the European Organization for the Research and Treatment of Cancer found that treating cancer that has metastasized to the brain with focal, high-dose radiation yields improved early results compared with surgical removal.
Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy.
A recent study confirmed the International Association for the Study of Lung Cancer's proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification.
For cancer patients, following the initial shock of their diagnosis, thoughts quickly turn to estimating how much precious time they have left with family and friends or whether certain treatments could prolong their life.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
